Dickinson K, Yee E, Vigil I, Schulick R, Zhu Y
Cancer Immunol Immunother. 2024; 73(12):253.
PMID: 39358616
PMC: 11447192.
DOI: 10.1007/s00262-024-03801-7.
Zhou Q, Chen Y, Liang Y, Sun Y
Metabolites. 2024; 14(6).
PMID: 38921452
PMC: 11205356.
DOI: 10.3390/metabo14060317.
McConnell B, Liang Z, Xu C, Han Y, Yun C
Am J Physiol Gastrointest Liver Physiol. 2024; 326(6):G631-G642.
PMID: 38593468
PMC: 11376986.
DOI: 10.1152/ajpgi.00269.2023.
Ruzza C, Argentieri M, Ferrari F, Armani E, Trevisani M, Marchini G
Front Pharmacol. 2023; 14:1267414.
PMID: 38035009
PMC: 10682101.
DOI: 10.3389/fphar.2023.1267414.
Hutka B, Varallyay A, Laszlo S, Toth A, Scheich B, Paku S
Acta Pharmacol Sin. 2023; 45(2):339-353.
PMID: 37816857
PMC: 10789874.
DOI: 10.1038/s41401-023-01175-7.
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer.
Dacheux M, Norman D, Tigyi G, Lee S
Pharmacol Ther. 2023; 245:108414.
PMID: 37061203
PMC: 10290275.
DOI: 10.1016/j.pharmthera.2023.108414.
Effects of lysophosphatidic acid on sling and clasp fibers of the human lower esophageal sphincter.
Feng Y, Wei W, Chen L, Liu J
Turk Gogus Kalp Damar Cerrahisi Derg. 2022; 30(3):404-409.
PMID: 36303683
PMC: 9580277.
DOI: 10.5606/tgkdc.dergisi.2022.22084.
Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects.
Zhang D, Decker A, Woodhouse K, Snyder R, Patel P, Harris D
Eur J Med Chem. 2022; 243:114741.
PMID: 36126387
PMC: 10155261.
DOI: 10.1016/j.ejmech.2022.114741.
An LPAR -antagonist that reduces nociception and increases pruriception.
Langedijk J, Araya E, Barroso A, Tolenaars D, Nazare M, Belabed H
Front Pain Res (Lausanne). 2022; 3:963174.
PMID: 35959236
PMC: 9360597.
DOI: 10.3389/fpain.2022.963174.
LPAR2-mediated action promotes human renal cell carcinoma via MAPK/NF-κB signaling to regulate cytokine network.
Wang Y, Qi Z, Li Z, Bai S, Damirin A
J Cancer Res Clin Oncol. 2022; 149(5):2041-2055.
PMID: 35857125
DOI: 10.1007/s00432-022-04197-6.
GPR55-Mediated Effects in Colon Cancer Cell Lines.
Hasenoehrl C, Feuersinger D, Kienzl M, Schicho R
Med Cannabis Cannabinoids. 2021; 2(1):22-28.
PMID: 34676330
PMC: 8489337.
DOI: 10.1159/000496356.
Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?.
Balijepalli P, Sitton C, Meier K
Cells. 2021; 10(8).
PMID: 34440828
PMC: 8394178.
DOI: 10.3390/cells10082059.
Endocannabinoid signaling pathways: beyond CB1R and CB2R.
Biringer R
J Cell Commun Signal. 2021; 15(3):335-360.
PMID: 33978927
PMC: 8222499.
DOI: 10.1007/s12079-021-00622-6.
PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.
Tang Y, Liu J, Wang Y, Yang L, Han B, Zhang Y
Autophagy. 2020; 17(10):2905-2922.
PMID: 33317392
PMC: 8525999.
DOI: 10.1080/15548627.2020.1847799.
Lysophosphatidic Acid Signalling in Nervous System Development and Function.
Birgbauer E
Neuromolecular Med. 2020; 23(1):68-85.
PMID: 33151452
PMC: 11420905.
DOI: 10.1007/s12017-020-08630-2.
Lysophosphatidic Acid Receptor 5 Contributes to Imiquimod-Induced Psoriasis-Like Lesions through NLRP3 Inflammasome Activation in Macrophages.
Gaire B, Lee C, Kim W, Sapkota A, Lee D, Choi J
Cells. 2020; 9(8).
PMID: 32707926
PMC: 7465035.
DOI: 10.3390/cells9081753.
Regulation of Tumor Immunity by Lysophosphatidic Acid.
Lee S, Dacheux M, Norman D, Balazs L, Torres R, Augelli-Szafran C
Cancers (Basel). 2020; 12(5).
PMID: 32397679
PMC: 7281403.
DOI: 10.3390/cancers12051202.
Lysophosphatidic Acid Induces Apoptosis of PC12 Cells Through LPA1 Receptor/LPA2 Receptor/MAPK Signaling Pathway.
Zhang J, Li Y, Wang C, Wang Y, Zhang Y, Huang L
Front Mol Neurosci. 2020; 13:16.
PMID: 32116549
PMC: 7016214.
DOI: 10.3389/fnmol.2020.00016.
Small-Molecule Lysophosphatidic Acid Receptor 5 (LPAR5) Antagonists: Versatile Pharmacological Tools to Regulate Inflammatory Signaling in BV-2 Microglia Cells.
Plastira I, Joshi L, Bernhart E, Schoene J, Specker E, Nazare M
Front Cell Neurosci. 2019; 13:531.
PMID: 31849616
PMC: 6897279.
DOI: 10.3389/fncel.2019.00531.
Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.
Xu Y
Cancers (Basel). 2019; 11(10).
PMID: 31658655
PMC: 6826372.
DOI: 10.3390/cancers11101523.